ArticleJournal of translational medicine2026
Combining spatial and single-cell transcriptome data to analyze tertiary lymphoid structures in clear cell renal cell carcinoma reveals prognostic biomarkers.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immunometabolic Stress and Immune Suppression in Clear-Cell Renal Cell Carcinoma: Perspectives in Therapeutic Strategy.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundAs the predominant and most aggressive subtype of renal cell carcinoma (RCC), clear cell RCC (ccRCC) represents the considerable heterogeneity present across RCC subtypes. Although tertiary lymphoid structures (TLS) are implicated in tumor immunity, their prognostic role and underlying mechanisms in ccRCC remain unclear. Characterizing TLS-associated genes may offer novel insights into disease progression and support improved risk stratification and personalized therapy.
methodsThe single-cell transcriptome and spatial transcriptome data were utilized to analyze the B-cell infiltration in ccRCC and to screen for differentially expressed genes within TLS of ccRCC. Next, consensus clustering and survival analysis based on Lasso-Cox regression were applied to identify TLS prognostic markers in ccRCC. Subsequently, a prognostic prediction model for ccRCC was established by integrating key clinical characteristics and these prognostic biomarkers. The immunofluorescence experiments were performed on ccRCC clinical specimens to validate the clinical relevance of proteins in candidate biomarkers for ccRCC.
resultsAberrant expression of three TLS-associated genes (CEMIP, PLA2G2A, and IGHGP) was associated with poor prognosis in ccRCC, identifying them as potential prognostic biomarkers. Then, the protein-coding biomarkers were validated in ccRCC pathological tissue samples by immunofluorescence. Mechanistically, aberrant expression underlies the functional transition in TLS from anti-tumor immunity to tumor promotion, potentially mediated by dysregulation of oncogenic processes via multi-pathway interactions. A prognostic model based on these biomarkers demonstrated high predictive accuracy.
conclusionsCombining single-cell analysis with spatial transcriptomic profiling identifies spatially-resolved functional heterogeneity in ccRCC-associated TLS, demonstrating their context-dependent immunomodulatory roles. Aberrant expression of specific TLS-associated proteins is associated with a functional transition from anti-tumor immunity to tumor promotion. CEMIP, PLA2G2A, and IGHGP may serve as potential prognostic biomarkers; derived models achieve high predictive accuracy, highlighting clinical potential. Immunofluorescence confirmed the enrichment of protein-level biomarkers within TLS in ccRCC clinical specimens. Our findings elucidate TLS-related genes regulating tumor-immune interactions, advancing understanding of ccRCC prognosis and providing tools for prediction and personalized therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.